智通财经记者 | 陈杨 智通财经编辑 | 谢欣 在行业媒体动脉网2018年的一篇报道中，天麦生物如此定位自己：在二代胰岛素上是跟随者，三代胰岛素上是竞争者，口服胰岛素上是引领者。 可以参考的是，同期，誉衡药业曾拟以不低于40亿元收购天麦生物不低于35%的可转让无负担股权，交易方亦承诺此后三年天麦生物净利润合计 达到18亿元。换而言之公司当时估值高达114亿元。不过该交易很快终止。 据天麦生物官网，2014年至2016年，公司先后完成二代胰岛素、三代（长效、速效）胰岛素类似物的开发、工艺放大及商业化规模的开发及生产 等工作。 智通财经注意到，当时，胰岛素确实是个好生意。据米内网数据，2016年，其在公立医疗机构终端市场规模约190亿元，诺和诺德、赛诺菲的单品 销售额约在25至35亿元，甘李药业、通化东宝单品销售额也各有13亿元。 而天麦生物更大的想象空间在于口服胰岛素。基于庞大的用药群体，这种让患者免于每天一针的给药方式的市场相当可观。 2015年，天麦生物与以色列Oramed公司签订投资协议及口服胰岛素大中华区技术许可协议。Oramed是一家以色列的纳斯达克上市公司。从公司名 上即可窥见，其致力于开发口服药物 ...

Group 1 - A recent incident in Fujian highlights the dangers of improperly taking medication, where a man experienced a severe drop in blood pressure after splitting a controlled-release antihypertensive tablet, leading to a medical emergency [1] - Medications labeled with "controlled-release," "sustained-release," or "enteric-coated" should be swallowed whole, as breaking or crushing them can lead to rapid drug release, potentially causing shock or death [1][2] - Controlled-release tablets are designed to release medication at a constant rate, allowing for once-daily dosing, while regular tablets require multiple doses throughout the day [2] Group 2 - Sustained-release tablets, while having a different manufacturing process than controlled-release tablets, also aim for slow drug release and should not be split, as this can lead to adverse reactions [4] - Enteric-coated tablets are designed to dissolve in the intestines rather than the stomach; splitting them can cause premature dissolution in the stomach, affecting efficacy and potentially irritating the gastric lining [4] - Capsules should not be opened, as this can expose the medication to stomach acid, affecting its release and increasing gastrointestinal side effects [4] Group 3 - Patients should be aware of the proper sequence and timing for taking medications, as this can impact their effectiveness and reduce the risk of adverse reactions [5] - It is advised to space the intake of traditional Chinese medicine and Western medicine by about half an hour, and to take certain medications after meals to minimize gastrointestinal irritation [5] - Storage conditions for medications, including temperature and humidity, are crucial for maintaining their efficacy; for example, insulin must be stored between 2°C and 8°C to remain effective [6][8]

Core Viewpoint - The Trump administration announced the launch of a new website called "TrumpRx" aimed at allowing Americans to purchase prescription drugs directly from manufacturers at significantly discounted prices, bypassing traditional insurance systems and intermediaries [2][3]. Group 1: Pricing Strategy - TrumpRx will enable consumers to buy specific drugs at government-negotiated discount prices, potentially reducing drug prices by as much as 300% to 600% or more in some cases [3][4]. - The initiative is based on agreements with over a dozen pharmaceutical companies, including Amgen, Eli Lilly, Gilead, and Pfizer, under a "most favored nation" pricing policy [4][5]. Group 2: Pharmaceutical Company Agreements - Pfizer was the first company to announce an agreement with the government, stating that patients could purchase its drugs at an average discount of 50%, covering most primary care and some specialty brand medications [4]. - Following Pfizer, the Trump administration secured similar agreements with several other pharmaceutical companies in late 2022 [5]. Group 3: Political and Expert Reactions - Some Democratic lawmakers and healthcare policy experts expressed skepticism about the effectiveness of TrumpRx, questioning whether it would provide substantial savings for consumers and highlighting the existing discounts available through other means [6][8]. - Concerns were raised regarding the legality and safety of expedited FDA approvals for participating drug companies, suggesting that rushed processes could be dangerous [7].

2026.02. 06 本文字数：1690，阅读时长大约3分钟 作者 | 第一财经 孙卓 当地时间周四（2月5日），特朗普发表全国电视讲话称将推出名为"特朗普药房"（TrumpRx）的新网站，旨在让美国民众以大幅折扣价格直接向药品制 造商购买处方药。 白宫发表声明称，TrumpRx的核心在于绕过中间环节和传统保险体系，以政府协议折扣价直接向制药商购买特定药品，从而为民众降低处方药价格。 特朗普表示，新的政府协议将改变这种局面。 "根据我的政府与制药公司谈判达成的协议，美国将支付所有国家中最低的价格。我们将获得世界上任何地方的最低价格。这就是你们将要支付的价 格。"特朗普说，"这些药价对美国来说将大幅下降——降幅高达300%、400%、500%，甚至600%。"特朗普说。"在某些情况下，降幅甚至更大。" 特朗普当天列举了一系列他声称价格将会降低的药物，包括辅助生育药物、胰岛素和减肥药等40多种药物。 白宫的声明称，这些价格反映了其与十多家制药公司-包括安进、礼来、吉利德和辉瑞等公司根据"最惠国"药品定价协议谈判达成的折扣。 和关税有关？ 特朗普当天在白宫的活动中说，"美国人长期以来一直在为药品支付全球最高的价格 ...

白宫发表声明称，TrumpRx的核心在于绕过中间环节和传统保险体系，以政府协议折扣价直接向制药商 购买特定药品。 当地时间周四（2月5日），特朗普发表全国电视讲话称将推出名为"特朗普药房"（TrumpRx）的新网 站，旨在让美国民众以大幅折扣价格直接向药品制造商购买处方药。 白宫发表声明称，TrumpRx的核心在于绕过中间环节和传统保险体系，以政府协议折扣价直接向制药商 购买特定药品，从而为民众降低处方药价格。 和关税有关？ 白宫的声明称，这些价格反映了其与十多家制药公司-包括安进、礼来、吉利德和辉瑞等公司根据"最惠 国"药品定价协议谈判达成的折扣。 据报道，在同每一家制药公司达成的协议中，特朗普政府都同意放弃对制药行业征收关税的计划，以换 取制药公司以折扣价向医疗补助计划（Medicaid）和通过TrumpRx直接向消费者销售药品。 在去年3月，特朗普签署一项行政命令称，制药公司已同意"以不高于其他可比国家的价格销售处方 药"，特朗普称，这可以被称为是一项药品定价的"最惠国待遇"政策。 特朗普当天在白宫的活动中说，"美国人长期以来一直在为药品支付全球最高的价格，而其他国家却只 需支付同样药品价格的零头。" ...

Core Viewpoint - The article discusses how the strategic purchasing mechanism of medical insurance, centered around centralized bulk purchasing and drug price negotiations, is reshaping China's pharmaceutical industry landscape [3]. Group 1: Policy Changes and Trends - Since 2018, China's pharmaceutical policy has shifted to a value-oriented and collaborative governance phase, with medical insurance transitioning from a passive payer to an active strategic purchaser [3][4]. - The establishment of a national drug price negotiation mechanism supports the accessibility of innovative and high-priced drugs, emphasizing clinical value and cost-effectiveness [4][5]. - The proportion of new drugs entering the medical insurance directory within the same year of approval has increased from 32% in 2019 to 97.6% in 2023, significantly reducing the time from drug approval to insurance reimbursement from five years to just over one year [4]. Group 2: Drug Procurement and Pricing - The centralized procurement system has expanded, with 490 types of drugs procured over eight years, covering various treatment areas including chronic diseases and cancer [7]. - In 2024, 28.6% of the newly negotiated drugs were cancer medications, and 71% of the new varieties were domestic innovative drugs, indicating a rapid shift towards high-value areas in the pharmaceutical industry [5][6]. Group 3: Challenges and Recommendations - The article highlights challenges such as inadequate quality supervision in bulk purchasing, insufficient collaboration between medical insurance and pharmaceutical innovation, and the need for improved access to rare disease medications [8][10]. - Recommendations include enhancing clinical monitoring of selected drugs, establishing a unified drug usage tracking system, and developing a multi-tiered payment system to address the accessibility of innovative drugs [10][11].

Core Viewpoint - Tonghua Dongbao Pharmaceutical Co., Ltd. has received an administrative regulatory measure from the Jilin Securities Regulatory Bureau, addressing issues related to the mixed use of properties with its controlling shareholder, lack of lease agreements, and rent payments, which the company is committed to rectify [1] Group 1: Regulatory Measures - The company acknowledges the regulatory measures and emphasizes its commitment to comply with relevant laws and regulations, aiming to enhance corporate governance [1] - The identified issues reflect weaknesses in the company's governance structure and independent management, prompting a comprehensive internal management system improvement [1] - The regulatory measures are characterized as routine oversight and are not expected to impact the company's normal production and operational activities [1] Group 2: Financial Performance and Growth - The company forecasts a net profit of approximately 1.242 billion yuan for 2025, indicating a turnaround from losses compared to the previous year [2] - The anticipated profit increase is primarily driven by the company's competitive advantage in insulin procurement, leading to rapid market share growth for insulin products [2] - The company has also seen significant growth in other products, such as liraglutide injection and empagliflozin tablets, contributing to a substantial rise in domestic sales revenue [2] Group 3: Strategic Focus - As a leading player in the domestic insulin market, the company plans to continue focusing on its core business, increasing R&D investment, and advancing international expansion [2] - The company aims to optimize its product structure and enhance core competitiveness while maintaining stable operational performance and improving corporate governance [2]

Core Viewpoint - The article discusses China's evolving role in global public health, particularly in the context of the United States' withdrawal from the World Health Organization (WHO), highlighting a shift from a charity-based model to an infrastructure and investment approach in health assistance [1][2][3] Group 1: Shift in Global Health Assistance Model - The traditional Western model of global health assistance, characterized by charity and donations from wealthy countries to multilateral organizations, is being replaced by China's development-focused approach, which emphasizes building local production capabilities [1][2] - China's "Health Silk Road" initiative promotes infrastructure development, such as building insulin production facilities in Nigeria and malaria drug factories in West Africa, prioritizing hard infrastructure over soft aid [1][2] Group 2: China's Role as a Global Health Stabilizer - China is positioning itself as a new stabilizer in global health by maintaining its financial commitments to the WHO and pledging support at the upcoming World Health Assembly, demonstrating its commitment to global health governance [2] - The absence of the U.S. has created an opportunity for China to define "global public goods" on its own terms, as seen during the COVID-19 pandemic when it positioned vaccines as global public products [2] Group 3: Competitive Landscape - The challenge for Western countries lies not in undermining China's contributions but in competing with its model by investing in local healthcare capabilities in developing nations rather than relying on traditional charity [3] - As the U.S. withdraws, China's approach becomes the only viable option for many countries, paving a new path in global health assistance [3]

Investment Rating - The report indicates a strong growth outlook for the company, with projected net profit for 2025 expected to reach between 1.1 billion to 1.2 billion, representing a year-on-year growth of 79%-95% [1] Core Insights - The company's growth is primarily driven by a significant improvement in its domestic insulin business, which saw a revenue increase of 45.6% in the first three quarters of 2025, characterized by both volume and price increases [2][4] - The successful selection of all six products in the 2024 national procurement for insulin has led to a more than 30% increase in procurement volume compared to the previous round, providing a substantial boost in sales certainty [4] - The company's gross margin has stabilized above 73% over the past two years, indicating effective cost control and product structure optimization, allowing it to convert procurement pressure into market share and profit [4][6] Domestic Business Performance - The company has captured a 30% market share in the third-generation insulin procurement, positioning itself as the leading domestic player, second only to Novo Nordisk, amidst a trend of domestic products replacing imports [6] - The company’s products are now available in over 40,000 medical institutions, with rapid growth particularly in grassroots markets [6] International Expansion - International sales revenue reached 350 million in the first three quarters of 2025, marking a 45.5% year-on-year increase [7] - A significant 10-year technology transfer and supply agreement with Brazil, valued at no less than 3 billion, positions the company as the sole approved solution for Brazil's national public health system [7][9] - The company is transitioning from merely exporting products to a more sophisticated model of technology output, which includes local production technology transfer and talent development [9] Research and Development Focus - The company is heavily investing in R&D, with R&D expenses accounting for 13.4% of revenue in the first three quarters of 2025 [10] - Key products in development include GZR4 (ultra-long-acting insulin), which is in Phase III clinical trials and aims to revolutionize patient treatment habits, and GZR18 (GLP-1 dual-week formulation), which has received FDA approval and shows promising weight loss results [11][12] - The company is also advancing GZR101 (premixed dual insulin) into Phase II clinical trials, aiming to provide more convenient treatment options [12] - The successful launch of either GZR4 or GZR18 could elevate the company from an "insulin expert" to a "comprehensive solution provider for metabolic diseases" [14]

Core Viewpoint - Ganli Pharmaceutical (603087.SH) is expected to achieve a net profit of 1.1 to 1.2 billion yuan in 2025, representing a year-on-year growth of 79% to 95%, driven by a significant recovery in its insulin business amidst procurement pressures [3][4]. Group 1: Core Business Growth - The growth of Ganli is primarily attributed to the substantial improvement in its domestic insulin business, with revenue increasing by 45.6% in the first three quarters of 2025, characterized by both volume and price increases [4][6]. - A key turning point was the successful participation in the 2024 national insulin procurement, where all six products were selected, leading to a more than 30% increase in procurement volume compared to the previous round [6]. - The company's gross margin has stabilized above 73% over the past two years, recovering from a significant drop post-2022 procurement, indicating effective cost control and product structure optimization [6][9]. Group 2: Market Position and Competition - Ganli's share of the third-generation insulin procurement volume has reached 30%, making it the leading domestic player, second only to Novo Nordisk, as foreign market shares decline [9]. - The company has expanded its product coverage to over 40,000 medical institutions, with rapid growth in grassroots markets [9]. Group 3: International Expansion - International sales revenue for Ganli reached 350 million yuan in the first three quarters of 2025, marking a 45.5% year-on-year increase [10]. - A significant breakthrough was a 10-year technical transfer and supply agreement with Brazil, valued at no less than 3 billion yuan, making Ganli the only approved solution for Brazil's national public health system [10][11]. - The company's strategy involves not just drug exports but also high-level "technology output," including local production technology transfer and talent training [11][12]. Group 4: Research and Development Focus - Ganli is heavily investing in research and development, with R&D expenses accounting for 13.4% of revenue in the first three quarters of 2025 [13]. - The company is targeting the next frontier in diabetes treatment with products like GZR4 (ultra-long-acting insulin) and GZR18 (GLP-1 dual-week formulation), both of which are in advanced clinical stages and have significant market potential [15][16]. - Ganli aims to transition from being an "insulin expert" to a "comprehensive solution provider for metabolic diseases" upon successful product launches [16].